287 related articles for article (PubMed ID: 35165282)
41. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
42. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
[TBL] [Abstract][Full Text] [Related]
43. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
[TBL] [Abstract][Full Text] [Related]
44. Epstein-Barr virus miR-BART2-5p and miR-BART11-5p regulate cell proliferation, apoptosis, and migration by targeting RB and p21 in gastric carcinoma.
Zhao MH; Liu W; Zhang X; Zhang Y; Luo B
J Med Virol; 2023 Jan; 95(1):e28338. PubMed ID: 36418188
[TBL] [Abstract][Full Text] [Related]
45. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.
Cai LM; Lyu XM; Luo WR; Cui XF; Ye YF; Yuan CC; Peng QX; Wu DH; Liu TF; Wang E; Marincola FM; Yao KT; Fang WY; Cai HB; Li X
Oncogene; 2015 Apr; 34(17):2156-66. PubMed ID: 25347742
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of ABI2 expression by EBV-miR-BART13-3p induces epithelial-mesenchymal transition of nasopharyngeal carcinoma cells through upregulation of c-JUN/SLUG signaling.
Huang J; Qin Y; Yang C; Wan C; Dai X; Sun Y; Meng J; Lu Y; Li Y; Zhang Z; Wu B; Xu S; Jin H; Yang K
Aging (Albany NY); 2020 Jan; 12(1):340-358. PubMed ID: 31907338
[TBL] [Abstract][Full Text] [Related]
48. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
[TBL] [Abstract][Full Text] [Related]
49. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Fang W; Zhang J; Hong S; Zhan J; Chen N; Qin T; Tang Y; Zhang Y; Kang S; Zhou T; Wu X; Liang W; Hu Z; Ma Y; Zhao Y; Tian Y; Yang Y; Xue C; Yan Y; Hou X; Huang P; Huang Y; Zhao H; Zhang L
Oncotarget; 2014 Dec; 5(23):12189-202. PubMed ID: 25361008
[TBL] [Abstract][Full Text] [Related]
50. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
[TBL] [Abstract][Full Text] [Related]
51. The Epstein-Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma.
Hsu CY; Yi YH; Chang KP; Chang YS; Chen SJ; Chen HC
PLoS Pathog; 2014 Feb; 10(2):e1003974. PubMed ID: 24586173
[TBL] [Abstract][Full Text] [Related]
52. Targeting of DICE1 tumor suppressor by Epstein-Barr virus-encoded miR-BART3* microRNA in nasopharyngeal carcinoma.
Lei T; Yuen KS; Xu R; Tsao SW; Chen H; Li M; Kok KH; Jin DY
Int J Cancer; 2013 Jul; 133(1):79-87. PubMed ID: 23280823
[TBL] [Abstract][Full Text] [Related]
53. Identification of multiple sclerosis-related genes regulated by EBV-encoded microRNAs in B cells.
Rang X; Liu Y; Wang J; Wang Y; Xu C; Fu J
Mult Scler Relat Disord; 2022 Mar; 59():103563. PubMed ID: 35114606
[TBL] [Abstract][Full Text] [Related]
54. Genetic variants in NKG2D axis and susceptibility to Epstein-Barr virus-induced nasopharyngeal carcinoma.
Viet NH; Trung NQ; Dong LT; Trung LQ; Espinoza JL
J Cancer Res Clin Oncol; 2021 Mar; 147(3):713-723. PubMed ID: 33392659
[TBL] [Abstract][Full Text] [Related]
55. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
[TBL] [Abstract][Full Text] [Related]
56. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr Virus Induces Adipocyte Dedifferentiation to Modulate the Tumor Microenvironment.
Liu SC; Tsang NM; Lee PJ; Sui YH; Huang CH; Liu TT
Cancer Res; 2021 Jun; 81(12):3283-3294. PubMed ID: 33824135
[TBL] [Abstract][Full Text] [Related]
58. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
[TBL] [Abstract][Full Text] [Related]
59. Analysis of Epstein-Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region.
Dias JM; Santana IVV; da Silva VD; Carvalho AL; Arantes LMRB
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233023
[TBL] [Abstract][Full Text] [Related]
60. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]